CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BIIB

Nusinersen

Phase 3
Biogen Inc. (BIIB)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Muscular Atrophy, Spinal

View Full Landscape
Drug Information

Target Indication

Muscular Atrophy, Spinal

Clinical Trial

NCT04729907

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA5/30/2017

Spinraza

Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.

OrphanAccelerated
View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.